Touting an off-label use is a big no-no when it comes to pharma marketing, and that's exactly what's landed Metuchen Pharmaceuticals in trouble with the FDA's promo police. The agency has slapped Metuchen with a warning letter for misleading risk and efficacy claims online and in print for erectile disfunction drug Stendra.
